The global market for biopharmaceutical contract manufacturing is likely to display strong growth in the forthcoming years. The strong growth of the market is mainly because of risk hedging practices among biopharmaceutical wherein manufacturing is outsourced to contract manufacturing organizations (CMOs). This allows biopharmaceutical companies to balance their risk and have sufficient time to attain clinical trial milestones. In addition, lack of manufacturing capabilities and high costs of R&D for biopharmaceutical products is compelling small companies to outsource manufacturing activities. Furthermore, strong technical capabilities of contract of CMOs in cell-line development, process development, and scale-up, along with rich pipeline of biologics such as multispecific monoclonal antibodies, viral vectors, peptides, and other oligonucleotides are fostering the biopharmaceutical contract manufacturing market.
On the downside, however, insufficient capacity of CMOs for large volume manufacture of biopharmaceutical drug substances, complexities involved in transferring biological components, and limited options for biopharmaceutical companies for large-volume manufacturing are bottlenecks to this market’s growth.
The global biopharmaceutical contract manufacturing market can be segmented in terms of product type, application, platform, therapeutic area, services, and region. By product type, the segments into which this market can be classified are interferons, vaccines, growth factors, monoclonal antibodies, recombinant hormones, and others. By platform, key segments into which the biopharmaceutical contract manufacturing market could be divided are mammalian and microbial. In terms of application, the key segments of the market are commercial and clinical. Depending upon therapeutic area, the key segments into which the biopharmaceutical contract management market could be segmented are oncology, metabolic disorders, respiratory diseases, autoimmune diseases, cardiovascular diseases, neurology, hematology, and others. Based on services, the key segments of the market could include manufacturing and research. The segment of manufacturing services could be further sub-segmented into bulk drugs and active pharmaceutical ingredient, advanced drug delivery formulations, packaging, and finished dose formulations.
Obtain the Report Brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=34412
Geography-wise, the global market for biopharmaceutical contract manufacturing market could be classified into North America, Asia Pacific, Europe, Latin America, and the Middle East & Africa. Among them, in 2016, North America held the leading position in this market. The region is likely to hold on to its dominant position through the forecast period ending in 2025.
Leading companies operating in the biopharmaceutical contract manufacturing market profiled in this report include Lonza Group, Rentschler Biotechnologies GmbH, Fujifilm Diosynth Biotechnologies, Abzena plc, Vetter Pharma International GmbH, Boehringer Ingelheim GmbH, Cytovance Biologics Inc., Samsung Biologics Co. Ltd., Catalent Inc., Patheon N.V., Ajinomoto Althea Inc., WuXi Biologics, and Pfizer CentreOne among others.